[ad_1]
|
| Yeon Ho Choi, professor of pediatric adolescents at Samsung Medical Center in Seoul, explains the symptoms of Crohn's disease. © News1 |
Scientific studies have shown that adolescents with Crohn's disease stop taking medication. The researchers confirmed that the lowest blood level of the biologic injection (infliximab) is badyzed and that the risk of recurrence drops more than 7 times.
Professor Choi Yeon-Ho of the Department of Pediatric Adolescents at the Samsung Medical Center and Professor Kang Byeong of the Kyungpook National University announced on March 24 that 63 patients with moderate Crohn's disease severe were followed and observed between January 2009 and June 2016. 19659003] According to the research team, the average age at diagnosis of Crohn's disease was 14.9 years and the median was 12 months or more. The researchers stopped the use of flicemax in these patients and confirmed the recurrence rate, which allowed 38 out of 63 (60.3%) patients to re-offend Crohn's disease. According to Kaplan-Meyer badysis, 19% of patients had a recurrence in the year following discontinuation of treatment, 62.2% in 4 years and 75.2% in 6 years.
The incidence of recurrence in 6 years was 55.5% when mucosal lesions were completely healed due to early disappearance of intestinal ulcers in infliximab. The remaining patients did not reproduce, even though they stopped the biologic injection. In particular, if the lowest blood level of infliximab is less than 2.5 μg / mL, the relative risk of relapse is reduced to 7.19 fold, leaving a scientific basis for interrupting the injections.
Crohn's disease manifests itself anywhere from mouth to anus Chronic inflammatory bowel disease is a chronic inflammatory bowel disease that affects approximately 25% of all patients. The problem was that it was difficult to easily stop the biological injections such as infliximab because of the high risk of recurrence in children and adolescents with a long period of illness. Biological injections are considered an innovative drug for the treatment of Crohn's disease, but the longer the period of use, the greater the chance of experiencing side effects such as infection or tumor.
As the situation continued, there was much controversy among the doctors about when to stop biological injections. Professor Yeon-ho Choi said: "This study opened a way for patients to cut off drugs and select patients for further treatment."
The results of this study were published in the Journal of the Journal of Chronicles and Collitis Crohn's and Colitis.
sj @
[ad_2]
Source link
